异动解读 | 亚盛医药财报亮眼，盘中大涨6.44%
周五盘中，亚盛医药（AAPG）股价大涨6.44%，引发市场广泛关注。这一显著涨幅主要源于公司日前发布的2024年度财报中披露的亮眼业绩。
根据亚盛医药公布的2024年全年业绩报告，公司实现营收9.81亿元人民币，同比大幅增长342%。增长的主要动力来自于多个方面，包括与武田制药的1亿美元选择权付款、核心产品耐立克（奥雷巴替尼）2.41亿元的强劲销售（同比增长52%），以及来自苏州信达的商业化许可费收入等。
除了财务表现优异外，亚盛医药在产品开发和商业化方面也取得了显著进展。公司另一核心产品APG-2575的新药上市申请已获国家药监局药品审评中心（CDE）受理并纳入优先审评。此外，亚盛医药今年1月成功登陆美国纳斯达克市场，成为2025年美股生物医药第一股，进一步彰显了其全球化战略布局。这些积极因素共同推动了投资者信心，促使股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available